Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Medical Disclaimer This website is for educational and informational purposes only
In pre-clinical models, BPC 157 has been observed to: Upregulate vascular endothelial growth factor (VEGF) , promoting new blood vessel formation in damaged tissue Modulate nitric oxide (NO) synthesis pathways, influencing vascular tone and healing cascades Interact with the growth hormone receptor system , potentially amplifying downstream tissue repair signaling Demonstrate cytoprotective effects along the gastrointestinal tract its native home territory as a gastric peptide Exhibit apparent neuroprotective properties in rodent models of CNS injury BPC 157 stability in gastric acid unusual for peptides has made it a focus of GI mucosal repair research
A receptor assay, structural study, in vitro model, preclinical model, and human study setting each answers a different kind of question
What lifestyle modifications can help reduce tinnitus factors
These monotherapy results established proof of concept that amylin receptor agonism alone can produce clinically meaningful weight reduction and informed the dose selection of 2.4 mg for the combination product CagriSema
